-
Recommendations on the Use of Structured Expert Elicitation Protocols for Healthcare Decision Making
-
ISPOR Strategic Plan 2030
-
Assessing Real-World Data From Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist
-
Mapping Health Technology Assessment Agency Approaches for Biosimilar Value Assessment
-
The PICOTS-ComTeC Framework for Defining Digital Health Interventions
-
Systematic Review of Outcomes for Assessment of Medication Adherence Enhancing Interventions
-
ISPOR 2024-2025 Top 10 HEOR Trends
-
Evolving Use of Health Technology Assessment in Medical Device Procurement—Global Systematic Review
-
Recommendations on the Selection, Development, and Modification of Performance Outcome (PerfO) Assessments
-
Updated Recommendations on Evidence Needed to Support Measurement Comparability Among Modes of Data Collection for Patient-Reported Outcome Measures
-
Quantitative Benefit-Risk Assessment in Medical Product Decision Making
-
A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health
-
HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects
-
How Useful Are Digital Health Terms for Outcomes Research?
-
Is IQWiG's 15% Threshold Universally Applicable in Assessing the Clinical Relevance of Patient-Reported Outcomes Changes?
-
Challenges of Health Technology Assessment in Pluralistic Healthcare Systems
-
Machine Learning Methods in Health Economics and Outcomes Research—The PALISADE Checklist
-
Designing and Implementing Deliberative Processes for Health Technology Assessment: Joint HTAi/ISPOR Task Force Report
-
Accounting For Preference Heterogeneity In Discrete-Choice Experiments
-
Are We Ready For A New Approach To Comparing Coverage And Reimbursement Policies For Medical Nutrition In Key Markets
-
Opportunities and Barriers to the Development and Use of Open Source Health Economic Models: A Survey
-
The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis
-
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022)
-
Comparisons of Food and Drug Administration and European Medicines Agency Risk Management Implementation for Recent Pharmaceutical Approvals
-
Being Precise About Precision Medicine: Report of the ISPOR Personalized Precision Medicine Special Interest Group
-
Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report
-
ISPOR Science Strategy
-
The Future of HE+OR
-
Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing
-
Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions - Report of the ISPOR Stated Preference Research Special Interest Group
-
Defining Patient Engagement in Research: Results of a Systematic Review and Analysis
-
Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report
-
Value of Information Analytical Methods - Report 2
-
Value of Information Analysis for Research Decisions - An Introduction Report 1
-
Rare Disease Terminology and Definitions - A Systematic Global Review
-
Health Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations from the Medical Devices and Diagnostics Special Interest Group
-
Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models
-
Methods for Measuring Multiple Medication Adherence: A Systematic Review
-
Medical Nutrition Terminology and Regulations in the United States and Europe
-
Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA
-
Economic Analysis of Vaccination Programs - Good Practices for Outcomes Research Task Force Report
-
Application of Constrained Optimization Methods in Health Services Research
-
Challenges in Research and Health Technology Assessment of Rare Disease Technologies:
-
A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report 7
-
A Health Economics Approach to US Value Assessment Frameworks—Introduction: An ISPOR Special Task Force Report 1
-
Review of Recent US Value Frameworks—A Health Economics Approach: An ISPOR Special Task Force Report 6
-
Approaches to Aggregation and Decision Making—A Health Economics Approach: An ISPOR Special Task Force Report 5
-
Objectives, Budgets, Thresholds, and Opportunity Costs—A Health Economics Approach: An ISPOR Special Task Force Report 4
-
An Overview of Value, Perspective, and Decision Context—A Health Economics Approach: An ISPOR Special Task Force Report 2
-
Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report 3
-
Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness
-
Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0
-
Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials
-
Constrained Optimization Methods in Health Services Research-An Introduction
-
Mapping to Estimate Health-State Utility from Non-Preference-Based Outcome Measures
-
Clinician-Reported Outcome Assessments of Treatment Benefit-Clinical Outcome Assessment Emerging Good Practices Task Force
-
Estimating Health-State Utility for Economic Models in Clinical Studies
-
Statistical Methods for the Analysis of Discrete-Choice Experiments
-
Multiple Criteria Decision Analysis for Health Care Decision Making - An Introduction: Report 1
-
Multiple Criteria Decision Analysis for Health Care Decision Making - Emerging Good Practices: Report 2
-
Initial Medication Adherence - Review and Recommendations for Good Practices in Outcomes Research: An ISPOR Medication Adherence and Persistence Special Interest Group Report
-
Clinical Outcome Assessments: A Conceptual Foundation Good Practices for Outcomes Research Task Force
-
Applying Dynamic Simulation Modeling Methods in Health Care Delivery Research - The SIMULATE Checklist
-
Selecting a Dynamic Simulation Modeling Method for Health Care Delivery Research - Part 2
-
Cost-Effectiveness Analysis Alongside Clinical Trials II - Good research practices task force report
-
PRO Data Collection in Clinical Trials Using Mixed Modes
-
Indirect Treatment Comparison/Network Meta-Analysis Study Questionnaire to Assess Study Relevance and Credibility to Inform Healthcare Decision-Making - Report 3
-
A Questionnaire to Assess the Relevance and Credibility of Observational Studies to Inform Health Care Decision Making - Report 1
-
Questionnaire to Assess Relevance and Credibility of Modeling Studies for Informing Health Care Decision Making - Report 2
-
Principles of Good Practice for Budget Impact Analysis II
-
Systematic Literature Review of Psychosocial and Behavioral Factors Associated with Initial Medication Adherence
-
Impact of Interventions on Medication Adherence and Blood Pressure Control in Patients with Essential Hypertension: A Systematic Review by the ISPOR Medication Adherence and Persistence Special Interest Group
-
A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars
-
Performance-Based Risk-Sharing Arrangements - Good Practices for Design, Implementation and Evaluation
-
Pediatric Patient-Reported Outcome Instruments for Research to Support Medical Product Labeling
-
Validation of Electronic Systems to Collect Patient-Reported Outcome (PRO) Data - Recommendations for Clinical Trial Teams
-
Checklist for Ascertaining Study Cohorts in Oncology Health Services Research Using Secondary Data
-
Constructing Experimental Designs for Discrete-Choice Experiments
-
Prospective Observational Studies to Assess Comparative Effectiveness
-
Modeling Good Research Practices - Overview: Report 1
-
Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research
-
Conceptualizing a Model: Report 2
-
State-Transition Modeling: Report 3
-
Modeling Using Discrete Event Simulation: Report 4
-
Dynamic Transmission Modeling: Report 5
-
Model Parameter Estimation and Uncertainty Analysis: Report 6
-
Model Transparency and Validation: Report 7
-
Content Validity - Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation Part 1
-
Content Validity – Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation Part 2
-
Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making Report 1
-
Conducting Indirect Treatment Comparison and Network Meta-Analysis Studies Report 2
-
Conjoint Analysis Applications in Health - A Checklist
-
Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy - Report of ISPOR Risk–Benefit Management Working Group
-
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations - ISPOR drug cost task force report - Part I
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective - ISPOR drug cost task force report - Part II
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective - ISPOR drug cost task force report - Part III
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and US Government Payers Perspectives ISPOR drug cost task force report - Part IV
-
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective - ISPOR drug cost task force report - Part V
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective - ISPOR drug cost task force report - Part VI
-
Costs of Medication Non adherence in Patients with Diabetes Mellitus: A Systematic Review and Critical Analysis of the Literature
-
Use of Existing Patient-Reported Outcome (PRO) Instruments and Their Modification
-
The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report
-
Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources - Task Force Report Part III
-
Good research practices for comparative effectiveness research - bias & confounding in the design - Task Force Report Part II
-
Good research practices for comparative effectiveness research – defining, reporting & interpreting - Task Force Report Part I
-
Multinational Trials – Recommendations on the Translations Required, Approaches to Using the Same Language in Different Countries, and the Approaches to Support Pooling the Data
-
Recommendations on Evidence Needed to Support Measurement Equivalence between Electronic and Paper-Based Patient-Reported Outcome (PRO) Measures
-
Transferability of Economic Evaluations Across Jurisdictions - Good research practices task force report
-
Understanding Medication Compliance and Persistence from an Economics Perspective
-
Medication Compliance and Persistence: Terminology and Definitions
-
Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases
-
Methods for Integrating Medication Compliance and Persistence in Pharmacoeconomic Evaluations
-
Principles of Good Practice for Budget Impact Analysis I
-
Using Real-World Data for Coverage and Payment Decisions
-
Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials
-
Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures
-
Use of Pharmacoeconomics Information
-
A Checklist for Retrospective Database Studies
-
Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation